As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: December 18, 2017
by Allison Inserro for AJMC:
In a discovery that could potentially pave the way for more targeted treatments, researchers announced that dementia with Lewy bodies (DLB) has a unique genetic profile, separate from those of Alzheimer disease (AD) or Parkinson disease (PD).
It is the first large-scale genetic study of this common type of dementia. Researchers also found that DLB has heritability traits similar to PD.
The genome-wide association study was conducted by a collaboration led by University College London (UCL), with 65 academics in 11 countries. Results were published December 15 in The Lancet Neurology.”Dementia with Lewy bodies accounts for 10%-15% of dementia cases, yet our understanding of it lags beyond the more well-known Alzheimer’s disease, partly because it’s commonly misdiagnosed,” said the study’s lead author, Dr Jose Bras, UCL Institute of Neurology and Alzheimer’s Society senior research fellow, in a statement. “Our findings clarify the disease’s distinctive genetic signature, which should, in the future, help improve clinical trials, and lead to more targeted treatments.”
Researchers genotyped 1743 patients with dementia with Lewy bodies (DLB)—including both clinical samples and 1324 pathological samples assessed post-mortem—and 4454 controls. They found that:
For the first time, researchers were able to identify a heritability estimate of DLB, 36%, which is similar to that of PD. The heritability was particularly high for 4 specific chromosomes, suggesting that further research could focus on those chromosomes to identify novel loci.
“As the gene loci that had previously been associated with DLB were also implicated in Alzheimer’s and Parkinson’s, it was unclear if DLB’s genetic roots were simply a combination of the other two diseases. We’ve confirmed that instead, it has its own unique genetic profile,” explained the study’s first author, Dr Rita Guerreiro, UCL Institute of Neurology and Alzheimer’s Society senior research fellow.
“The selection of study participants has been a substantial challenge in dementia trials. Our findings can be used to identify more clearly which type of dementia each person has, so that they can take part in the right clinical trial, which could lead to better treatments and diagnostic tools,” she said.
“Despite DLB being one of the most common forms of dementia in older people, until now there simply hasn’t been enough information on its causes, so the finding that up to 36% of cases might be genetically inherited is a real revelation,” said Dr Doug Brown, research director at the Alzheimer’s Society, which funded the study. The Lewy Body Society also provided funding.
Dementia is a growing problem for people as they age, but it often goes undiagnosed. Now investigators at Harvard-affiliated Massachusetts General Hospital (MGH) and Beth Israel Deaconess Medical Center have discovered and validated a marker of...
While Jeanne Beker may be best known for her work in fashion journalism and television, she’s also an Honourary Board Member of the Women’s Brain Health Initiative (WBHI), a Canadian and U.S. foundation that works to combat brain-aging diseases and protect...
People who experience post-traumatic stress disorder may be twice as likely to have dementia later in life, according to a new study — a finding with important implications for the coronavirus pandemic. The...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.